Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Immatics N.V. before investing.

In this article, we go over a few key elements for understanding Immatics N.V.’s stock price such as:

• Immatics N.V.’s current stock price and volume
• Why Immatics N.V.’s stock price changed recently
• Upgrades and downgrades for IMTX from analysts
• IMTX’s stock price momentum as measured by its relative strength

About Immatics N.V. (IMTX)

Before we jump into Immatics N.V.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Want to learn more about Immatics N.V.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Immatics N.V..

Immatics N.V.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Immatics N.V.’s stock price was $8.660.

Immatics N.V. is down 5.87% from its previous closing price of $9.200.

During the last market session, Immatics N.V.’s stock traded between $8.575 and $9.200. Currently, there are approximately 155.25 million shares outstanding for Immatics N.V..

Immatics N.V.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Immatics N.V. Stock Price History

Immatics N.V.’s (IMTX) price is currently down 14.51% so far this month.

During the month of July, Immatics N.V.’s stock price has reached a high of $10.890 and a low of $8.170.

Over the last year, Immatics N.V. has hit prices as high as $12.410 and as low as $5.050. Year to date, Immatics N.V.’s stock is down 17.52%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Immatics N.V. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Immatics N.V.’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Immatics N.V.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Immatics N.V.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Immatics N.V.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Immatics N.V. (IMTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Immatics N.V.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Immatics N.V. has a weighted four-quarter relative price strength of 0.50%, which translates to a Momentum Score of 55 and is considered to be Average.

Want to learn more about how Immatics N.V. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Immatics N.V. Stock Price: Bottom Line

As of July 31, 2026, Immatics N.V.’s stock price is $8.660, which is down 5.87% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Immatics N.V. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.